PMID- 26986104
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 11
DP  - 2016 Mar
TI  - Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese 
      Subjects With Newly Diagnosed Type 2 Diabetes.
PG  - e2961
LID - 10.1097/MD.0000000000002961 [doi]
LID - e2961
AB  - To compare the therapeutic effects of different regimens in Chinese obese type 2 
      diabetic mellitus (T2DM) patients. From October 2013 to July 2014, a total of 166 
      T2DM outpatients who attended the Shanghai Changhai Hospital and the Yijishan 
      Hospital of Wannan Medical College were randomly assigned into an experimental 
      sitagliptin/metformin combined with low caloric diet group (n = 115) and an 
      insulin glargine combined with metformin control group (n = 51). Inclusion 
      criteria were body mass index (BMI) >/= 25 kg/m and diagnosed with T2DM with 
      glycosylated hemoglobin (glycated hemoglobin A1C [HbA1c]) >9%. Main outcome 
      parameters were fasting plasma glucose, postprandial plasma glucose, BMI, HbA1c, 
      fasting C-peptide, 2-h postprandial C-peptide, triglyceride (TG), total 
      cholesterol (TC), high-density cholesterol (HDL-C), and low-density cholesterol 
      (LDL-C), which were determined by the 75 g steamed-bun meal tolerance test before 
      and 4, 8, 12, and 24 weeks after the treatment started. Treatment costs and life 
      quality were also assessed. BMI, HbA1C, TG, TC, and LDL were significantly more 
      reduced (P < 0.000) and HbA1c significantly better improved in the experimental 
      group than in the control group (<6.5% in 24 [20.87%] vs 2 [3.92%], P < 0.001; 
      <7% in 65 [56.52%] vs 12 [23.53%], P < 0.001). Quality of life scores in the 
      experimental group increased more than in the control group (P < 0.001). The 
      costs for the experimental group medication were less than for other regimens. 
      For obese T2DM patients diagnosed with a glycosylated hemoglobin level >9%, oral 
      sitagliptin/metformin combined with a low caloric diet effectively and 
      economically maintained glycemic control and significantly improved life quality.
FAU - Ji, Ming
AU  - Ji M
AD  - From the Department of Endocrinology,Shanghai Changhai Hospital,No.168 Changhai 
      Road,Shanghai 200433,China (MJ, JC, DZ) and Department of Endocrinology, Yijishan 
      Hospital of Wannan Medical College,Wuhu,Anhui,241000,China (LX, DZ), China.
FAU - Xia, Libin
AU  - Xia L
FAU - Cao, Jingzhu
AU  - Cao J
FAU - Zou, Dajin
AU  - Zou D
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 9100L32L2N (Metformin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Body Mass Index
MH  - *Diabetes Mellitus, Type 2/blood/complications/diagnosis/drug therapy
MH  - Drug Monitoring/methods
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects
MH  - *Insulin Glargine/administration & dosage/adverse effects
MH  - Male
MH  - *Metformin/administration & dosage/adverse effects
MH  - Middle Aged
MH  - *Obesity/complications/diagnosis
MH  - *Sitagliptin Phosphate/administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC4839885
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/03/18 06:00
MHDA- 2016/08/02 06:00
PMCR- 2016/03/18
CRDT- 2016/03/18 06:00
PHST- 2016/03/18 06:00 [entrez]
PHST- 2016/03/18 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
PHST- 2016/03/18 00:00 [pmc-release]
AID - 00005792-201603150-00011 [pii]
AID - 10.1097/MD.0000000000002961 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Mar;95(11):e2961. doi: 10.1097/MD.0000000000002961.